<bill session="116" type="h" number="6019" updated="2022-02-08T23:17:38Z">
  <state datetime="2020-02-28">REFERRED</state>
  <status>
    <introduced datetime="2020-02-28"/>
  </status>
  <introduced datetime="2020-02-28"/>
  <titles>
    <title type="display">Cure the Coronavirus Act</title>
    <title type="official" as="introduced">To expand the tropical disease product priority review voucher program to encourage treatments for coronavirus.</title>
    <title type="short" as="introduced">Cure the Coronavirus Act</title>
  </titles>
  <sponsor bioguide_id="J000294"/>
  <cosponsors>
    <cosponsor bioguide_id="C001067" joined="2020-04-14"/>
    <cosponsor bioguide_id="C001068" joined="2020-04-14"/>
    <cosponsor bioguide_id="C001097" joined="2020-02-28"/>
    <cosponsor bioguide_id="H001090" joined="2020-06-15"/>
    <cosponsor bioguide_id="H001081" joined="2020-04-14"/>
    <cosponsor bioguide_id="H001056" joined="2020-02-28"/>
    <cosponsor bioguide_id="K000210" joined="2020-02-28"/>
    <cosponsor bioguide_id="T000483" joined="2020-04-07"/>
  </cosponsors>
  <actions>
    <action datetime="2020-02-28">
      <text>Introduced in House</text>
    </action>
    <action datetime="2020-02-28" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Emergency medical services and trauma care"/>
    <term name="Infectious and parasitic diseases"/>
  </subjects>
  <amendments/>
  <summary date="2020-03-10T15:26:20Z" status="Introduced in House">Cure the Coronavirus Act

This bill expands the tropical disease priority review voucher program to include COVID-19 (a respiratory disease caused by a novel coronavirus), thereby providing manufacturers with incentives for development of a vaccine.</summary>
</bill>
